FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a method for producing a therapeutically active fused protein comprising a targeted targeting group and at least one immunomodulating moiety, as well as to a preparation for weakening T-cell activation in cancer cells containing an effective amount of homogeneous therapeutically active fused proteins obtained by the above method. Also disclosed is a nucleic acid encoding a fusion protein containing a targeted targeting group and at least one immunomodulatory moiety. Invention also relates to an expression vector comprising the aforementioned nucleic acid.
EFFECT: invention enables efficient production of a therapeutically active fused protein for weakening T-cell activation in cancer cells.
10 cl, 64 dwg, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME | 2014 |
|
RU2662991C2 |
| TARGETED/IMMUNOMODULATING FUSION PROTEINS AND METHODS FOR THEIR OBTAINING | 2013 |
|
RU2636342C2 |
| TARGETED TGF BETA INHIBITION | 2015 |
|
RU2752424C2 |
| ANGIOPOIETIN-2-SPECIFIC COUPLING AGENTS | 2005 |
|
RU2404992C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| ANTIBODY-FYNOMER CONJUGATES | 2015 |
|
RU2732226C2 |
| ANTI-PD-1 ANTIBODIES, METHOD FOR THEIR PRODUCTION, AND METHOD OF APPLICATION | 2016 |
|
RU2656181C1 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTIBODIES TO INTERLEUKIN-1ALPHA, AND APPLICATION METHODS THEREOF | 2013 |
|
RU2666915C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
